<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662017000300407</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Enfermedad granulomatosa crónica]]></article-title>
<article-title xml:lang="en"><![CDATA[Chronic granulomatous disease]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Medrano-E'Vers]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales-Hernández]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valencia-López]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Salcedo]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Ángeles Clínica Londres ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Ángeles Clínica Londres ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Ángeles Clínica Londres ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Ángeles Clínica Londres ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<volume>33</volume>
<numero>3</numero>
<fpage>407</fpage>
<lpage>414</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662017000300407&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662017000300407&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662017000300407&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La enfermedad granulomatosa crónica es una enfermedad genéticamente heterogénea caracterizada por infecciones bacterianas recurrentes y fúngicas que se distinguen por la formación de granulomas. Su frecuencia en Estados Unidos es de aproximadamente 1:250,000 nacidos vivos. Es causada por defectos en el fagocito nicotinamida adenina dinucleótido fosfato oxidasa (NADPH), que constituye el fagocito oxidasa (phox). Estos defectos genéticos dan como resultado la incapacidad de los fagocitos (neutrófilos, monocitos y macrófagos) para destruir ciertos microbios. El diagnóstico se realiza mediante pruebas de función de los neutrófilos, y luego el defecto exacto se determina por genotipo. Las infecciones son causadas generalmente por microorganismos catalasa-positivos. Los sitios frecuentes de infección son los pulmones, la piel, los ganglios linfáticos y el hígado. La formación de granulomas es especialmente un problema en el tubo gastrointestinal y el aparato genitourinario. La enfermedad granulomatosa crónica puede aparecer en cualquier momento desde la infancia hasta la adultez, pero la mayoría de los pacientes son diagnosticados antes de los cinco años de edad, por lo que se destaca la importancia clínica de este caso ocurrido en un adulto mayor.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Chronic granulomatous disease (CGD) is a genetically heterogeneous condition characterized by recurrent, life-threatening bacterial and fungal infections and granuloma formation. The frequency of CGD, in the United States is approximately 1:250,000 live births. CGD is caused by defects in the phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, which constitutes the phagocyte oxidase (phox). These genetic defects result in the inability of phagocytes (neutrophils, monocytes, and macrophages) to destroy certain microbes. The diagnosis is made by neutrophil function testing, and then the exact defect is determined by genotyping. Infections are generally caused by catalase-positive micro-organisms (most bacterial and all fungal pathogens are catalase positive). The frequent sites of infection are lung, skin, lymph nodes, and liver. The formation of granulomata is especially problematic in the gastrointestinal and genitourinary tracts. May present at any time from infancy to late adulthood, but the majority of patients are diagnosed as toddlers and children before the age of five years. Whereby emphasis is made on the clinical significance of this case, which occurs in an older adult.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[enfermedad granulomatosa crónica]]></kwd>
<kwd lng="en"><![CDATA[chronic granulomatous disease]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Caracterización clínica y genético-molecular de un paciente con enfermedad granulomatosa crónica ligada al X Reporte de una nueva mutación asociada al splicing. Caso clínico]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Vélez]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mendivil]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Chil Pediatr]]></source>
<year>2014</year>
<volume>85</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>213-21</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Chronic granulomatous disease [Spanish] Enfermedad granulomatosa cronica]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suarez]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
<name>
<surname><![CDATA[del Valle Perez]]></surname>
<given-names><![CDATA[LO]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Salgado]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[IG]]></given-names>
</name>
<name>
<surname><![CDATA[Segura]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Cuba Hematol Inmunol y Hemoter]]></source>
<year>2014</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>280-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Enfermedad granulomatosa crónica]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez-Cardona]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yamazaki-Nakashimada]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa-Padilla]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Alerg Mex]]></source>
<year>2009</year>
<volume>56</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>165-74</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mycobacterial disease in patients with chronic granulomatous disease: A retrospective analysis of 71 cases]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lugo-Reyes]]></surname>
<given-names><![CDATA[SO]]></given-names>
</name>
<name>
<surname><![CDATA[Blancas Galicia]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Aksu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Borges de Oliveira]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Enfermedad granulomatosa crónica: tres casos clínicos con diferentes formas de presentación]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Espinoza]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Butte]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Palma]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Norambuena]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Chil Pediatr]]></source>
<year>2015</year>
<volume>86</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>112-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Diagnóstico de enfermedad granulo-matosa crónica; pacientes y portadoras]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramírez-Vargas]]></surname>
<given-names><![CDATA[NG]]></given-names>
</name>
<name>
<surname><![CDATA[Berrón-Ruiz]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Berrón-Pérez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Blancas-Galicia]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Alerg Mex]]></source>
<year>2011</year>
<volume>58</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>120-5</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[1,2,3 dihidrorodamina, una técnica accesible y útil para la detección de pacientes y portadoras de enfermedad granulomatosa crónica Experiencia en el Instituto Nacional de Pediatría]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blancas-Galicia]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa-Padilla]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa-Rosales]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Alerg Asma Inmunol Pedriatr]]></source>
<year>2013</year>
<volume>22</volume>
<page-range>96-100</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Recent advances in chronic granulomatous disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldblatt]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[J Infect]]></source>
<year>2014</year>
<volume>69</volume>
<numero>^sS1</numero>
<issue>^sS1</issue>
<supplement>S1</supplement>
<page-range>S32-5</page-range><publisher-name><![CDATA[Elsevier Ltd]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Chronic granulomatous disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holland]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<source><![CDATA[Hematol Oncol Clin North Am]]></source>
<year>2013</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>89-99</page-range><publisher-name><![CDATA[Elsevier Inc]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Killing activity of neutro-phils is mediated through activation of proteases by K+ flux]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reeves]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<source><![CDATA[Nature]]></source>
<year>2002</year>
<volume>416</volume>
<page-range>291</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Clinical, functional, and genetic characterization of chronic granulomatous disease in 89 Turkish patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Köker]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
<name>
<surname><![CDATA[Camcioglu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[van Leeuwen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kiliç]]></surname>
<given-names><![CDATA[S§]]></given-names>
</name>
<name>
<surname><![CDATA[Barlan]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Yilmaz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2013</year>
<volume>132</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1156-63.e5</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cutting edge infection by the agent of human granulocytic ehrlichiosis prevents the respiratory burst by down-regulating gp91phox]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Banerjee]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Anguita]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Roos]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fikrig]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[J Immunol]]></source>
<year>2000</year>
<volume>164</volume>
<page-range>3946</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Chronic granulomatous disease: Overview and hematopoietic stem cell transplantation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Marciano]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Deravin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zarember]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Holland]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Malech]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2011</year>
<volume>127</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1319-26</page-range><publisher-name><![CDATA[Elsevier Ltd]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Targeted gene addition in human CD34+ hematopoietic cells for correction of X-linked chronic granulomatous disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Ravin]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Reik]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[P-Q]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Biotechnol]]></source>
<year>2016</year>
<page-range>1-8</page-range><publisher-name><![CDATA[Nature Publishing Group]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
